title: Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.
abstract: Marburg virus (MARV) has been associated with sporadic episodes of hemorrhagic fever, including a recent highly publicized outbreak in Angola that produced severe disease and significant mortality in infected patients. MARV is also considered to have potential as a biological weapon. Recently, we reported the development of a promising attenuated, replication-competent vaccine against MARV based on recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of the Musoke strain of MARV (VSVDeltaG/MARVGP-Musoke). We used this vaccine to demonstrate complete protection of cynomolgus monkeys against a homologous MARV challenge. While these results are highly encouraging, an effective vaccine would need to confer protection against all relevant strains of MARV. Here, we evaluated the protective efficacy of the VSVDeltaG/MARVGP-Musoke vaccine against two heterologous MARV strains, the seemingly more pathogenic Angola strain and the more distantly related Ravn strain. In this study, seven cynomolgus monkeys were vaccinated with the VSVDeltaG/MARVGP-Musoke vector. Three of these animals were challenged with the Angola strain, three with the Ravn strain, and a single animal with the Musoke strain of MARV. Two animals served as controls and were each injected with a nonspecific VSV vector; these controls were challenged with the Angola and Ravn strains, respectively. Both controls succumbed to challenge by day 8. However, none of the specifically vaccinated animals showed any evidence of illness either from the vaccination or from the MARV challenges and all of these animals survived. These data suggest that the VSVDeltaG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains.
authors.affiliation: Virology Division, USAMRIID, Fort Detrick, MD 21702-5011, USA.
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Daddario-DiCaprio
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Geisbert
authors.forename: Joan B
authors.initials: JB
authors.lastname: Geisbert
authors.forename: Ute
authors.initials: U
authors.lastname: Ströher
authors.forename: Lisa E
authors.initials: LE
authors.lastname: Hensley
authors.forename: Allen
authors.initials: A
authors.lastname: Grolla
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Fritz
authors.forename: Friederike
authors.initials: F
authors.lastname: Feldmann
authors.forename: Heinz
authors.initials: H
authors.lastname: Feldmann
authors.forename: Steven M
authors.initials: SM
authors.lastname: Jones
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D003429:Cross Reactions / Q000276:immunology; D008252:Macaca fascicularis; D008379:Marburg Virus Disease / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D029024:Marburgvirus / Q000145:classification* / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D010802:Phylogeny; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014613:Vaccines, Attenuated / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014765:Viral Vaccines / Q000276:immunology*; D014766:Viremia / Q000097:blood / Q000276:immunology / Q000821:virology
chemical_list: D000906:Antibodies; D011994:Recombinant Proteins; D014613:Vaccines, Attenuated; D014764:Viral Proteins; D014765:Viral Vaccines